BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessBioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 TrialBy Nasdaq OMXMay 25, 2017, 12:03 PM UTC
BusinessSummit Announces Key Appointments to Strengthen Research and Development TeamBy Nasdaq OMXMay 23, 2017, 11:07 AM UTC
BusinessSummit Announces Key Appointments to Strengthen Research and Development TeamBy Nasdaq OMXMay 23, 2017, 11:07 AM UTC
